Jeffrey A. Lieberman, M.D. is a Professor and the Constance and Stephen Lieber Chair in Psychiatry at the Columbia University, Vagelos College of Physicians and Surgeons. Throughout his forty-year career he has focused on research and clinical care of patients with serious mental illness. In addition to his academic and clinical activities, Dr. Lieberman has played a significant role influencing government and social policy, educating health care providers and the public in an effort to reduce stigma and improve access to and quality of mental health care.
Dr. Lieberman’s research on the neurobiology, pharmacology and treatment of schizophrenia and related psychotic disorders has advanced our understanding and treatment of mental illness and led to the transformative mental health care strategy for the early detection and prevention of schizophrenia.
Dr. Lieberman has authored or co-authored over 800 articles published in scientific literature and wrote or edited 17 books on mental illness, psychopharmacology and psychiatry. He is the recipient of many awards including the Lieber Prize for Schizophrenia Research from NARSAD (BBRF), the Adolph Meyer Award from the American Psychiatric Association (APA) the Research Award from the National Alliance of Mental Illness among others. Dr. Lieberman is or has been a member of the Advisory committee for Neuropharmacologic and Psychopharmacologic Drugs of the FDA, the Planning Board for the Surgeon General’s Report on Mental Health, Chair of the Committee on Research on Psychiatric Treatments of the American Psychiatric Association (APA), and the APA Work Group for the Development of Schizophrenia Treatment Guidelines.
In 2000 he was elected to the National Academy of Medicine, in 2010 fellowship in the American Association for the Advancement of Science (AAAS) and served as President of the American Psychiatric Association in 2013 and 2014. For his innovative public mental health initiatives during the COVID-19 pandemic, he was named to the Power 50 in Mental Health by New York City and New York State in 2021.
Dr. Lieberman’s work has extended beyond biomedical research and clinical psychiatry into public policy and advocacy for improving mental health care, enhancing awareness and diminishing the stigma of mental illness. In this context, Dr. Lieberman actively contributed to government policy and legislation including the Mental Health Parity and Addiction Equity Act, The Patient Protection and Affordable Care Act and the Helping Families in Mental Health Crisis Act and has been a frequent public spokesperson in the media on mental illness and psychiatry. This motivated him to write the critically acclaimed book Shrinks: The Untold Story of Psychiatry (Little Brown 2015) for general audiences and deliver a TED Talk on Stigma and Mental Illness. Shrinks inspired the production of a four-part series, titled Mysteries of Mental Illness, that was nationally broadcast on PBS June 22 and 24, 2022.
His new book, Malady of the Mind: Schizophrenia and the Path to Prevention published by Charles A. Scribner’s of Simon and Shuster will be released in February 2023.
• Professor and Constance and Stephen Lieber Chair, Department
of Psychiatry, College of Physicians and Surgeons, Columbia
• Attending Psychiatrist, Columbia University Medical Center of
the New York-Presbyterian Hospital
• President, American Psychiatric Association (2013-2014)
Awards & Recognition
• Best Doctors in America ® (2003-2022)
• City & State’s Mental Health Power 50 (2021)
• Distinguished Service Award, American Psychiatric Association (APA) (2017)
• Scientific Research Award, National Alliance on Mental Illness
• Brain & Behavior Research Foundation Distinguished
Investigator Grant (2007, 1999)
• Adolph Meyer Award, American Psychiatric Association (2007)
• Lieber Prize for Outstanding Achievement in Schizophrenia
Research, National Association for Research in Schizophrenia and Affective Disorders (NARSAD) (2006).
• Lilly Neuroscience Award, The Collegium Internationale Neuro-Psychopharmacologicum (2002)
• Dana Alliance for Brain Initiatives (DABI)
• National Academy of Sciences Institute of Medicine
• American College of Psychiatrists, Fellow
• American Association for the Advancement of Science, Fellow
• American College of Neuropsychopharmacology, Fellow
• American Psychiatric Association, Distinguished Fellow
• American Psychopathological Association, Fellow
• Collegium Internationale NeuroPsychopharmacologicum (C.I.N.P.)
• New York Academy of Science
• Society for Biological Psychiatry
• Society for Neuroscience
Dr. Lieberman’s research has been supported by grants from the
National Institutes of Health and the NARSAD, Stanley, and Mental
Illness Foundations and has focused on the neurobiology,
pharmacology and treatment of schizophrenia and related
psychotic disorders. In this context, his work has advanced our
understanding of the natural history and pathophysiology of
schizophrenia and the pharmacology and clinical effectiveness
of antipsychotic drugs. In terms of the latter, he served as
Principal Investigator of the Clinical Antipsychotic Trials of
Intervention Effectiveness Research Program (CATIE), sponsored
by the NIMH. He also currently serves as Principal Investigator on the newly awarded NIMH contract Recovery After an Initial Schizophrenic Episode (RAISE) and will lead a multi-institution research team in developing and testing an evidence-based strategic intervention for early psychosis to demonstrate how treatment at the onset of symptoms can prevent the debilitating effects of schizophrenia and related psychotic disorders.
• Cognitive Remediation in Patients with Schizophrenia Stabilized on Lurasidone
• Evaluating Efficacy and Safety of RO4917838
• How a New Drug, DAR-0100A, Affects Memory, How You Think, And How You Make Decisions
• Testing Whether Investigational Drug RO4917838 is Safe and Can Improve Sub-Optimally
Controlled Symptoms in Patients With Schizophrenia
• Studying metabolic changes in non-psychotic adults taking the antipsychotic medications
Fanapt (iloperidone) or Zyprexa (olanzapine)